Clinical Trials Directory

Trials / Active Not Recruiting

Active Not RecruitingNCT06462391

Adapting and Piloting Acceptance and Commitment Therapy (ACT) for Severe Premenstrual Mood Symptoms

Adapting and Piloting Acceptance and Commitment Therapy (ACT) for Severe Premenstrual Mood Symptoms: An Open-label Feasibility Study of ACT-PM

Status
Active Not Recruiting
Phase
N/A
Study type
Interventional
Enrollment
50 (estimated)
Sponsor
Women's College Hospital · Academic / Other
Sex
Female
Age
18 Years
Healthy volunteers
Not accepted

Summary

In the weeks prior to menstruation, many individuals experience mood and physical symptoms that negatively impact their quality of life and functioning. Approximately 5% of women and menstruating individuals have such severe symptoms that they meet criteria for Premenstrual Dysphoric Disorder (PMDD). Further, of those with underlying mood disorders (i.e., depression, bipolar disorder) about 60% have cyclical worsening of symptoms classified as premenstrual exacerbation (PME). Both PMDD and PME are associated with significant impairment, yet limited effective options exist to treat these conditions. In this project, the investigators will adapt and evaluate an Acceptance and Commitment Therapy (ACT) group for PMDD and PME, entitled ACT-Premenstrual (ACT-PM), delivered virtually to maximize accessibility. The investigators will examine whether ACT-PM is feasible to deliver and whether it is acceptable to group participants and those facilitating the group. The study will lay the groundwork for future research to determine if the group is effective. If effective, the intervention could be scaled up to improve quality of life and outcomes for individuals suffering from PMDD and PME.

Conditions

Interventions

TypeNameDescription
BEHAVIORALAcceptance and Commitment Therapy (ACT) GroupPsychotherapy group (delivered virtually)

Timeline

Start date
2024-12-01
Primary completion
2026-06-30
Completion
2026-12-31
First posted
2024-06-17
Last updated
2025-12-22

Locations

2 sites across 1 country: Canada

Source: ClinicalTrials.gov record NCT06462391. Inclusion in this directory is not an endorsement.